Iterum Therapeutics plc
ITRM
$1.03
-$0.05-4.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.93% | -6.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.90% | 22.91% | |||
| Operating Income | 24.90% | -22.91% | |||
| Income Before Tax | -10.05% | -19.98% | |||
| Income Tax Expenses | -81.62% | 338.71% | |||
| Earnings from Continuing Operations | -8.01% | -21.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.01% | -21.95% | |||
| EBIT | 24.90% | -22.91% | |||
| EBITDA | 30.13% | -22.96% | |||
| EPS Basic | 18.88% | -0.70% | |||
| Normalized Basic EPS | 17.33% | 0.91% | |||
| EPS Diluted | 18.29% | -0.70% | |||
| Normalized Diluted EPS | 17.33% | 0.91% | |||
| Average Basic Shares Outstanding | 33.14% | 21.10% | |||
| Average Diluted Shares Outstanding | 33.14% | 21.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||